Minimizing the learning curve for robotic-assisted radical cystectomy
A single-surgeon, retrospective, cohort study
DOI:
https://doi.org/10.5489/cuaj.8279Keywords:
Robotic, Bladder Cancer, Cystectomy, MIS, Innovation, Learning curveAbstract
INTRODUCTION: Studies published to date have suggested non-inferiority of roboticassisted radical cystectomy (RARC) compared to open radical cystectomy (ORC), while few centers in Canada have adopted this approach. Though multifactorial, the learning curve and operative time are often discussed barriers. Herein, we present outcomes from the largest Canadian cohort of RARC performed to date.
METHODS: We conducted a retrospective chart review of all patients undergoing RARC by a single surgeon with greater than 1500 robot-assisted radical prostatectomy (RARP) experience at our institution from May 2020 to December 2021. Clinicopathological, intraoperative, and postoperative data, as well as complications in the first 90 days, were collected. Regression analysis was used to determine the relationship between case volume and operative time/lymph node yield.
RESULTS: A total of 31 patients underwent RARC during the study period, 26 of which were male. The median length of stay was six days (Q1–Q3 5–10), while days alive and out of hospital at 90 days were 83 days (Q1–Q3 80–85). Soft tissue margins were positive in 9.6% (3/31) of patients. Median lymph node yield was 17.0 lymph nodes (Q1–Q3 11–23). Median operative time was 241 minutes (Q1–Q3 228–252) in the ileal conduit group and 320 minutes (Q1–Q3 302–337) in the neobladder group. We observed four Clavien-Dindo grade >3 complications. The 90-day readmission rate and mortality rate were 17.2% (5) and 0% (0), respectively. There was no correlation between case volume and any outcome variables.
CONCLUSIONS: Previous high-volume experience performing RARP reduces the learning curve for performing RARC, with similar short-term outcomes to high-volume centers.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:
- Post the Article on any Web site
- Translate or authorize a translation of the Article
- Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
- Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.
The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.
You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.
The CUA also requires you to warrant the following:
- That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
- That all individuals who have made a substantive contribution to the article are acknowledged;
- That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
- That the Article does not libel or violate the privacy rights of any third party.
